Ohio State Navbar


Diabetes Dialogue Series 2014

The Diabetes Dialogue is a series formulated to provide the latest breakthroughs in diabetes research and clinical practice to the medical community. In particular, the meeting will focus on non-pharmacological intervention in the management of obesity and diabetes.While there is no doubt that medication treatment is effective in most patients, it is also clear that it is extremely difficult to achieve the American Diabetes Association Recommended AIC goal of less that 7% in most patients. Alternative approaches are needed to complement the medication treatment of patients with diabetes.

The   prevalence of diabetes has increased exponentially over past 3 decades. Although, there is tremendous understanding of the development of diabetes and benefits of glucose control, the current approach to glucose control has several limitations. The primary goals of diabetes care are to maintain health, prevent long term complications and prevent hypoglycemia. In this regard, the fear of hypoglycemia has limited the ability for most of our patients to achieve normal glucose control as assessed by A1C. Indeed, with innovations in new insulin and oral medications, the A1C has decreased from 9.1% to 8.1%. In addition, for the past 2 decades, the life expectancy gap between patients with diabetes and non – diabetic subjects has narrowed by 15 years and mortality has decreased by 43%. However, there are concerns that better technology will be needed to essentially normalize the A1C and further reduce the mortality gap. These technological advances will depend on new innovations such as new insulin delivery devices, remote glucose sensors and monitors and new technologies in islet cell transplantation or tissue replacement. Ultimately, physiologic replacement of insulin will be necessary to ensure normalization of glucose control without hypoglycemia using tissue insulin delivery therapies.

The Ohio State University Medical Center, Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Ohio State University Medical Center, Center for Continuing Medical Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

2014 Diabetes Dialogue: Emerging Controversies in Diabetes

Affordable Care Act (Obama  Care): Impact on Diabetes Care in Ohio; March 13, 2014

  • Review the  diabetes associated health care cost
  • Discuss the potential impact of ACA  on diabetic patients
  • Discuss the  impact of ACA on prevention of diabetes
  • Discuss life span of care of patients with diabetes.

Initiation of insulin in Type 2 diabetes: What are the Controversies? June 12, 2014

  • Identify patients with type 2 diabetes that are candidates for insulin therapy.
  •  Identify barriers, from both the patient’s and provider’s perspective, to initiating insulin.
  •  Discuss strategies to optimize success when starting a patient on insulin.

Lipids and CVD Outcomes in Diabetes.  What is the New Evidence for Statins? September 11, 2014

  • To discuss the controversies of the old lipid guidelines.
  • To discuss the rationale for the new lipid guidelines.
  • To discuss the controversies of the new lipid guidelines
  • To discuss the utility of the new guidelines in patients with diabetes
  • To discuss the anti-lipid drug recommendations based on new guidelines

Selection of DPP IV. And SGRT2 Blockers and GLP-1 Analogues: New Controversies; December 11, 2014

  • Identify new pathophysiology of type 2 Diabetes
  • Describe the role of GLP-1 Analogues, DDP IV Inhibitors and SGLT2 Receptor Inhibitors in managing Type 2 Diabetes
  • Explain effective strategies in selecting new anti-diabetic medications
  • Assess controversies surrounding the use of GLP-1 Analogues, DDP IV Inhibitors and SGLT2 Receptor

For Brochure, click here.

For registration, click here.